CoChat
Sign Up
Cited by 3

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Lifestyle Modification and Medical Management of Hypertrophic Cardiomyopathy

Heitner, Stephen B., Fischer, Katherine L.·2019·Cardiology Clinics
DOI 10.1016/j.ccl.2018.08.004
Open this paper in CoChat — free account

Abstract

Hypertrophic cardiomyopathy is a heterogenous condition associated with a myriad of symptoms. Just as in other disease states, the aim of medical therapy is the alleviation of suffering, improvement of longevity, and the prevention of complications. This article focuses on the associated comorbidities seen in patients with hypertrophic cardiomyopathy, potential lifestyle interventions, and conventional medical treatments for symptomatic hypertrophic cardiomyopathy.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.ccl.2018.08.004

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 60

  1. Maron, 2018, Global burden of hypertrophic cardiomyopathy, JACC Heart Fail, 6, 376, 10.1016/j.jchf.2018.03.004 · DOI
  2. Maron, 2003, Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy, N Engl J Med, 348, 295, 10.1056/NEJMoa021332 · DOI · Paper page
  3. Maron, 2018, Clinical spectrum and management of heart failure in hypertrophic cardiomyopathy, JACC Heart Fail, 6, 353, 10.1016/j.jchf.2017.09.011 · DOI
  4. Maron, 1999, Clinical course of hypertrophic cardiomyopathy in a regional United States cohort, JAMA, 281, 650, 10.1001/jama.281.7.650 · DOI
  5. Cecchi, 1995, Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population, J Am Coll Cardiol, 26, 1529, 10.1016/0735-1097(95)00353-3 · DOI
  6. Spirito, 1989, Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population, N Engl J Med, 320, 749, 10.1056/NEJM198903233201201 · DOI
  7. Cannan, 1995, Natural history of hypertrophic cardiomyopathy. A population-based study, 1976 through 1990, Circulation, 92, 2488, 10.1161/01.CIR.92.9.2488 · DOI
  8. Maron, 2012, Hypertrophic cardiomyopathy with longevity to 90 years or older, Am J Cardiol, 109, 1341, 10.1016/j.amjcard.2011.12.027 · DOI
  9. Feiner, 2013, Post-prandial upright exercise echocardiography in hypertrophic cardiomyopathy, J Am Coll Cardiol, 61, 2487, 10.1016/j.jacc.2013.02.079 · DOI
  10. Finocchiaro, 2017, Impact of demographic features, lifestyle, and comorbidities on the clinical expression of hypertrophic cardiomyopathy, J Am Heart Assoc, 6
  11. Paz, 1996, The effect of the ingestion of ethanol on obstruction of the left ventricular outflow tract in hypertrophic cardiomyopathy, N Engl J Med, 335, 938, 10.1056/NEJM199609263351305 · DOI · Paper page
  12. Kansal, 2010, Drink more, and eat less: advice in obstructive hypertrophic cardiomyopathy, Am J Cardiol, 106, 1313, 10.1016/j.amjcard.2010.06.061 · DOI
  13. Gersh, 2011, 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, J Am Coll Cardiol, 58, 2703, 10.1016/j.jacc.2011.10.825 · DOI
  14. Authors/Task Force Members, 2014, 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC), Eur Heart J, 35, 2733, 10.1093/eurheartj/ehu284 · DOI · Paper page
  15. Teare, 1958, Asymmetrical hypertrophy of the heart in young adults, Br Heart J, 20, 1, 10.1136/hrt.20.1.1 · DOI
  16. Maron, 1996, Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles, JAMA, 276, 199, 10.1001/jama.1996.03540030033028 · DOI · Paper page
  17. Alpert, 2015, Sports and exercise in athletes with hypertrophic cardiomyopathy, Clin Sports Med, 34, 489, 10.1016/j.csm.2015.03.005 · DOI
  18. Maron, 2009, Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006, Circulation, 119, 1085, 10.1161/CIRCULATIONAHA.108.804617 · DOI
  19. Maki, 1998, Predictors of sudden cardiac death in hypertrophic cardiomyopathy, Am J Cardiol, 82, 774, 10.1016/S0002-9149(98)00455-X · DOI
  20. Maron, 2000, The paradox of exercise, N Engl J Med, 343, 1409, 10.1056/NEJM200011093431911 · DOI
  21. Reineck, 2013, Physical activity and other health behaviors in adults with hypertrophic cardiomyopathy, Am J Cardiol, 111, 1034, 10.1016/j.amjcard.2012.12.018 · DOI
  22. Bonner, 2018, Psychological impact of a positive gene result for asymptomatic relatives at risk of hypertrophic cardiomyopathy, J Genet Couns, 27, 1040, 10.1007/s10897-018-0218-8 · DOI
  23. Sweeting, 2016, Physical activity in hypertrophic cardiomyopathy: prevalence of inactivity and perceived barriers, Open Heart, 3, e000484, 10.1136/openhrt-2016-000484 · DOI
  24. Saberi, 2018, Exercise and hypertrophic cardiomyopathy: time for a change of heart, Circulation, 137, 419, 10.1161/CIRCULATIONAHA.117.029989 · DOI
  25. Dejgaard, 2018, Vigorous exercise in patients with hypertrophic cardiomyopathy, Int J Cardiol, 250, 157, 10.1016/j.ijcard.2017.07.015 · DOI
  26. Saberi, 2017, Effect of moderate-intensity exercise training on peak oxygen consumption in patients with hypertrophic cardiomyopathy: a randomized clinical trial, JAMA, 317, 1349, 10.1001/jama.2017.2503 · DOI · Paper page
  27. Klempfner, 2015, Efficacy of exercise training in symptomatic patients with hypertrophic cardiomyopathy: results of a structured exercise training program in a cardiac rehabilitation center, Eur J Prev Cardiol, 22, 13, 10.1177/2047487313501277 · DOI
  28. Canepa, 2013, Comparison of clinical presentation, left ventricular morphology, hemodynamics, and exercise tolerance in obese versus nonobese patients with hypertrophic cardiomyopathy, Am J Cardiol, 112, 1182, 10.1016/j.amjcard.2013.05.070 · DOI
  29. Olivotto, 2013, Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy, J Am Coll Cardiol, 62, 449, 10.1016/j.jacc.2013.03.062 · DOI
  30. Konecny, 2014, Sleep-disordered breathing in hypertrophic cardiomyopathy: challenges and opportunities, Chest, 146, 228, 10.1378/chest.14-0084 · DOI
  31. Nerbass, 2013, Obstructive sleep apnea and hypertrophic cardiomyopathy: a common and potential harmful combination, Sleep Med Rev, 17, 201, 10.1016/j.smrv.2012.06.006 · DOI
  32. Prinz, 2011, Incidence of sleep-disordered breathing in patients with hypertrophic cardiomyopathy, Congest Heart Fail, 17, 19, 10.1111/j.1751-7133.2010.00196.x · DOI
  33. Pedrosa, 2010, Sleep quality and quality of life in patients with hypertrophic cardiomyopathy, Cardiology, 117, 200, 10.1159/000321718 · DOI
  34. Konecny, 2010, Interactions between sleep disordered breathing and atrial fibrillation in patients with hypertrophic cardiomyopathy, Am J Cardiol, 105, 1597, 10.1016/j.amjcard.2010.01.023 · DOI
  35. Konecny, 2015, Decreased exercise capacity and sleep-disordered breathing in patients with hypertrophic cardiomyopathy, Chest, 147, 1574, 10.1378/chest.14-1498 · DOI
  36. Aggarwal, 2015, Hypertrophic cardiomyopathy associated with sleep apnea: serious implications and cogent management strategy, Expert Rev Cardiovasc Ther, 13, 277, 10.1586/14779072.2015.1004314 · DOI
  37. Morgan, 2008, Psychiatric disorders in hypertrophic cardiomyopathy, Gen Hosp Psychiatry, 30, 49, 10.1016/j.genhosppsych.2007.09.005 · DOI
  38. Ingles, 2008, Psychosocial impact of specialized cardiac genetic clinics for hypertrophic cardiomyopathy, Genet Med, 10, 117, 10.1097/GIM.0b013e3181612cc7 · DOI
  39. Igoumenou, 2012, Depression in patients with hypertrophic cardiomyopathy: is there any relation with the risk factors for sudden death?, Heart Asia, 4, 44, 10.1136/heartasia-2012-010099 · DOI
  40. Lampert, 2010, Emotional stress triggers symptoms in hypertrophic cardiomyopathy: a survey of the Hypertrophic Cardiomyopathy Association, Pacing Clin Electrophysiol, 33, 1047, 10.1111/j.1540-8159.2010.02770.x · DOI
  41. Christiaans, 2009, Quality of life and psychological distress in hypertrophic cardiomyopathy mutation carriers: a cross-sectional cohort study, Am J Med Genet A, 149a, 602, 10.1002/ajmg.a.32710 · DOI
  42. Wynn, 2018, Examining the psychosocial impact of genetic testing for cardiomyopathies, J Genet Couns, 27, 927, 10.1007/s10897-017-0186-4 · DOI
  43. Axelsson, 2015, Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial, Lancet Diabetes Endocrinol, 3, 123, 10.1016/S2213-8587(14)70241-4 · DOI
  44. Maron, 2018, Effect of spironolactone on myocardial fibrosis and other clinical variables in patients with hypertrophic cardiomyopathy, Am J Med, 131, 837, 10.1016/j.amjmed.2018.02.025 · DOI
  45. Olivotto, 2018, Efficacy of ranolazine in patients with symptomatic hypertrophic cardiomyopathy: the RESTYLE-HCM randomized, double-blind, placebo-controlled study, Circ Heart Fail, 11, e004124, 10.1161/CIRCHEARTFAILURE.117.004124 · DOI
  46. Elliott, 2018, Evolving story of clinical trials in hypertrophic cardiomyopathy, Circ Heart Fail, 11, e004572, 10.1161/CIRCHEARTFAILURE.117.004572 · DOI
  47. Ho, 2017, The design of the valsartan for attenuating disease evolution in early sarcomeric hypertrophic cardiomyopathy (VANISH) trial, Am Heart J, 187, 145, 10.1016/j.ahj.2017.02.008 · DOI
  48. Cherian, 1966, Beta-adrenergic blockade in hypertrophic obstructive cardiomyopathy, Br Med J, 1, 895, 10.1136/bmj.1.5492.895 · DOI
  49. Adelman, 1970, Long-term propranolol therapy in muscular subaortic stenosis, Br Heart J, 32, 804, 10.1136/hrt.32.6.804 · DOI
  50. Flamm, 1968, Muscular subaortic stenosis. Prevention of outflow obstruction with propranolol, Circulation, 38, 846, 10.1161/01.CIR.38.5.846 · DOI
  51. Gombar, 2017, Beta-blockers inferior to calcium channel blockers in hypertrophic cardiomyopathy, Circulation, 136, A21307
  52. Ho, 2015, Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression, JACC Heart Fail, 3, 180, 10.1016/j.jchf.2014.08.003 · DOI
  53. Epstein, 1981, Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy, Circulation, 64, 437, 10.1161/01.CIR.64.3.437 · DOI
  54. Pollick, 1988, Disopyramide in hypertrophic cardiomyopathy. I. Hemodynamic assessment after intravenous administration, Am J Cardiol, 62, 1248, 10.1016/0002-9149(88)90268-8 · DOI
  55. Pollick, 1988, Disopyramide in hypertrophic cardiomyopathy. II. Noninvasive assessment after oral administration, Am J Cardiol, 62, 1252, 10.1016/0002-9149(88)90269-X · DOI
  56. Pollick, 1982, Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide, N Engl J Med, 307, 997, 10.1056/NEJM198210143071607 · DOI
  57. Louie, 1994, Hypertrophic cardiomyopathy, Prog Cardiovasc Dis, 36, 275, 10.1016/S0033-0620(05)80036-2 · DOI
  58. Coppini, 2013, Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy, Circulation, 127, 575, 10.1161/CIRCULATIONAHA.112.134932 · DOI
  59. Gentry, 2016, Ranolazine for treatment of angina or dyspnea in hypertrophic cardiomyopathy patients (RHYME), J Am Coll Cardiol, 68, 1815, 10.1016/j.jacc.2016.07.758 · DOI
  60. Bazoukis, 2018, Impact of ranolazine on ventricular arrhythmias - A systematic review, J Arrhythm, 34, 124

Cited by

Sorted by citations

See all 3

Metadata

Authors
Heitner, S. B., & Fischer, K. L.
Venue
Cardiology Clinics
Publisher
Elsevier BV
Published
2019-02
Volume
37
Issue
1
Pages
45-54
ISSN
0733-8651
DOI
10.1016/j.ccl.2018.08.004
Cited by
3
References
3
Language
en
Licence
Funders
MyoKardia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review